Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
Blood
|
September 2, 2020
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
Wenbin Xiao, Alexander Chan, Michael R Waarts, et al.
Haematologica
|
December 8, 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia
Wenbin Xiao, Aaron D Goldberg, Christopher A Famulare, et al.
Transplantation and Cellular Therapy
|
April 13, 2026
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations
Moataz Ellithi, Sandeep Raj, Maria Bromberg, et al.
Cancer Discovery
|
July 2, 2020
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition
Sheng F Cai, S Haihua Chu, Aaron D Goldberg, et al.
Transplantation and Cellular Therapy
|
May 25, 2021
Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy
Corrado Zuanelli Brambilla, Stephanie M Lobaugh, Josel D Ruiz, et al.
Blood Advances
|
May 4, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
Joseph G W McCarter, David Nemirovsky, Christopher A Famulare, et al.
Leukemia & Lymphoma
|
September 3, 2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
Jan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, et al.
Cell
|
March 10, 2010
Distinct factors control histone variant H3.3 localization at specific genomic regions
Aaron D Goldberg, Laura A Banaszynski, Kyung-Min Noh, et al.
Haematologica
|
April 2, 2026
Hypomethylating agents plus venetoclax <i>versus</i> intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia
Guillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, et al.
American Journal of Hematology
|
October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
Maximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
Blood
|
September 2, 2020
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
Wenbin Xiao, Alexander Chan, Michael R Waarts, et al.
Haematologica
|
December 8, 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia
Wenbin Xiao, Aaron D Goldberg, Christopher A Famulare, et al.
Transplantation and Cellular Therapy
|
April 13, 2026
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations
Moataz Ellithi, Sandeep Raj, Maria Bromberg, et al.
Cancer Discovery
|
July 2, 2020
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition
Sheng F Cai, S Haihua Chu, Aaron D Goldberg, et al.
Transplantation and Cellular Therapy
|
May 25, 2021
Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy
Corrado Zuanelli Brambilla, Stephanie M Lobaugh, Josel D Ruiz, et al.
Blood Advances
|
May 4, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
Joseph G W McCarter, David Nemirovsky, Christopher A Famulare, et al.
Leukemia & Lymphoma
|
September 3, 2021
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
Jan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, et al.
Cell
|
March 10, 2010
Distinct factors control histone variant H3.3 localization at specific genomic regions
Aaron D Goldberg, Laura A Banaszynski, Kyung-Min Noh, et al.
Haematologica
|
April 2, 2026
Hypomethylating agents plus venetoclax <i>versus</i> intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia
Guillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, et al.
American Journal of Hematology
|
October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
Maximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.
Page
of 7